Insulin combined with Acarbose may cause further lowering of blood glucose and increase hypoglycemia potential, including rare cases of hypoglycemic shock. Dosage adjustments recommended.
Source: NLP:acarbose
Acarbose Interactions
Brand names: Acarbose
alpha-Glucosidase Inhibitor · alpha Glucosidase Inhibitors
Route: Oral
Contraindications
CONTRAINDICATIONS Acarbose tablets are contraindicated in patients with known hypersensitivity to the drug. Acarbose tablets are contraindicated in patients with diabetic ketoacidosis or cirrhosis. Acarbose tablets are also contraindicated in patients with inflammatory bowel disease, colonic ulceration, partial intestinal obstruction or in patients predisposed to intestinal obstruction. In addition, acarbose tablets are contraindicated in patients who have chronic intestinal diseases associated with marked disorders of digestion or absorption and in patients who have conditions that may deteriorate as a result of increased gas formation in the intestine.
Pregnancy & Breastfeeding
Pregnancy Teratogenic Effects: Pregnancy Category B. The safety of acarbose tablets in pregnant women has not been established. Reproduction studies have been performed in rats at doses up to 480 mg/kg (corresponding to 9 times the exposure in humans, based on drug blood levels) and have revealed no evidence of impaired fertility or harm to the fetus due to acarbose. In rabbits, reduced maternal body weight gain, probably the result of the pharmacodynamic activity of high doses of acarbose in the intestines may have been responsible for a slight increase in the number of embryonic losses. However, rabbits given 160 mg/kg acarbose (corresponding to 10 times the dose in man, based on body surface area) showed no evidence of embryotoxicity and there was no evidence of teratogenicity at a dose 32 times the dose in man (based on body surface area). There are, however, no adequate and well-controlled studies of acarbose tablets in pregnant women. Because animal reproduction studies are not always predictive of the human response, this drug should be used during pregnancy only if clearly needed. Because current information strongly suggests that abnormal blood glucose levels during pregnancy are associated with a higher incidence of congenital anomalies as well as increased neonatal morbidity and mortality, most experts recommend that insulin be used during pregnancy to maintain blood glucose levels as close to normal as possible.
16 interactions on record
Calcium channel-blocking drugs produce hyperglycemia and may lead to loss of blood glucose control in patients receiving Acarbose. Close observation for loss of glucose control is recommended.
Source: NLP:acarbose
Acarbose + CharcoalModerate
Charcoal is an intestinal adsorbent that may reduce the effect of Acarbose and should not be taken concomitantly.
Source: NLP:acarbose
Acarbose + CorticosteroidsModerate
Corticosteroids produce hyperglycemia and may lead to loss of blood glucose control in patients receiving Acarbose. Close observation for loss of glucose control is recommended.
Source: NLP:acarbose
Acarbose + DigoxinModerate
Acarbose changes the bioavailability of digoxin when coadministered, which may require digoxin dose adjustment.
Source: NLP:acarbose
Acarbose + DiureticsModerate
Diuretics may produce hyperglycemia and lead to loss of blood glucose control. Patient should be closely observed for loss of blood glucose control.
Source: NLP:acarbose
Acarbose + EstrogensModerate
Estrogens produce hyperglycemia and may lead to loss of blood glucose control in patients receiving Acarbose. Close observation for loss of glucose control is recommended.
Source: NLP:acarbose
Acarbose + IsoniazidModerate
Isoniazid produces hyperglycemia and may lead to loss of blood glucose control in patients receiving Acarbose. Close observation for loss of glucose control is recommended.
Source: NLP:acarbose
Acarbose + NiacinModerate
Nicolinic acid produces hyperglycemia and may lead to loss of blood glucose control in patients receiving Acarbose. Close observation for loss of glucose control is recommended.
Source: NLP:acarbose
Acarbose + Oral ContraceptivesModerate
Oral contraceptives produce hyperglycemia and may lead to loss of blood glucose control in patients receiving Acarbose. Close observation for loss of glucose control is recommended.
Source: NLP:acarbose
Acarbose + PancreatinModerate
Pancreatin is a digestive enzyme preparation that may reduce the effect of Acarbose and should not be taken concomitantly.
Source: NLP:acarbose
Acarbose + PancrelipaseModerate
Amylase is a digestive enzyme preparation that may reduce the effect of Acarbose and should not be taken concomitantly.
Source: NLP:acarbose
Acarbose + PhenothiazinesModerate
Phenothiazines produce hyperglycemia and may lead to loss of blood glucose control in patients receiving Acarbose. Close observation for loss of glucose control is recommended.
Source: NLP:acarbose
Acarbose + PhenytoinModerate
Phenytoin produces hyperglycemia and may lead to loss of blood glucose control in patients receiving Acarbose. Close observation for loss of glucose control is recommended.
Source: NLP:acarbose
Acarbose + ThiazidesModerate
Thiazides produce hyperglycemia and may lead to loss of blood glucose control in patients receiving Acarbose. Close observation for loss of glucose control is recommended.
Source: NLP:acarbose
Acarbose + ThyroidModerate
Thyroid products produce hyperglycemia and may lead to loss of blood glucose control in patients receiving Acarbose. Close observation for loss of glucose control is recommended.
Source: NLP:acarbose